银屑病及银屑病关节炎孕妇的母婴结局:系统综述与荟萃分析
该系统综述与荟萃分析纳入16项观察性研究,比较银屑病或银屑病关节炎(PsA)孕妇与一般人群或健康对照的妊娠结局。结果显示,银屑病疾病孕妇不良母体结局风险显著升高,包括剖宫产、早产、(前期)子痫、妊娠期糖尿病和妊娠期高血压,但胎儿并发症风险无统计学显著增加。亚组分析中PsA的风险估计值似乎更大,但无统计学差异。
要点
- 银屑病/PsA孕妇剖宫产、早产、(前期)子痫、妊娠期糖尿病和妊娠期高血压风险显著升高。
- 胎儿并发症(小于胎龄儿、低出生体重、先天畸形、Apgar<7、新生儿死亡、死产)风险无统计学显著增加。
- PsA亚组母体风险估计值似乎更大,但无统计学差异;日常实践需密切监测孕前及孕期母体临床状态。
核心结论
- 银屑病和PsA孕妇不良母体事件风险升高,但不良新生儿事件风险无统计学显著增加。
研究设计与样本
- 系统综述与荟萃分析,检索多个电子数据库自建库至2020年8月3日及所选文章参考文献列表。
- 纳入报告至少一项妊娠结局的观察性研究,比较银屑病或PsA孕妇与一般人群或健康对照。
- 共纳入16项研究,采用随机效应模型合并数据,以比值比(OR)和95%CI表示。
主要发现
- 与一般人群相比,银屑病疾病孕妇剖宫产风险OR为1.33(1.17,1.52)。
- 早产风险OR为1.32(1.15,1.52),(前期)子痫风险OR为1.28(1.14,1.43)。
- 妊娠期糖尿病风险OR为1.19(1.10,1.30),妊娠期高血压风险OR为1.30(1.18,1.44)。
- 小于胎龄儿OR为1.02(0.93,1.11),低出生体重OR为1.15(0.93,1.42),先天畸形OR为1.03(0.93,1.14)。
- Apgar评分<7的OR为1.07(0.81,1.39),新生儿死亡OR为1.13(0.90,1.43),死产OR为1.19(0.95,1.50)。
关键数值与推荐
- 母体结局:剖宫产OR 1.33(1.17,1.52)、早产OR 1.32(1.15,1.52)、(前期)子痫OR 1.28(1.14,1.43)、妊娠期糖尿病OR 1.19(1.10,1.30)、妊娠期高血压OR 1.30(1.18,1.44)。
- 胎儿/新生儿结局:小于胎龄儿OR 1.02(0.93,1.11)、低出生体重OR 1.15(0.93,1.42)、先天畸形OR 1.03(0.93,1.14)、Apgar<7 OR 1.07(0.81,1.39)、新生儿死亡OR 1.13(0.90,1.43)、死产OR 1.19(0.95,1.50)。
- 亚组分析:银屑病或PsA孕妇母体结局结果相似,PsA风险估计值似乎更大但无统计学差异。
临床怎么用
- 日常实践中需密切监测银屑病和PsA孕妇孕前及孕期的母体临床状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Psoriasis and PsA are inflammatory diseases that affect women in their reproductive years. We aimed to investigate whether maternal psoriasis and PsA are associated with adverse pregnancy outcomes. METHODS: We searched multiple electronic databases from inception to 3 August 2020, and reference lists of selected articles. Observational studies reporting at least one pregnancy outcome in women with psoriasis or PsA with a comparator of general population or healthy subjects were included. Data were pooled by random-effects models and expressed as odds ratio (OR) and 95% CI. RESULTS: Overall, 16 studies were included in the meta-analysis. The pooled analyses showed pregnant women with psoriatic diseases have a significantly higher risk of adverse maternal outcomes compared with the general population [caesarean delivery: 1.33 (1.17, 1.52); preterm birth: 1.32 (1.15, 1.52); (pre)eclampsia: 1.28 (1.14, 1.43); gestational diabetes: 1.19 (1.10, 1.30); gestational hypertension: 1.30 (1.18, 1.44)]. However, no statistically increased risks of fetal complications were observed in women with psoriatic diseases [small for gestational age: 1.02 (0.93, 1.11); low birth weight: 1.15 (0.93, 1.42); congenital malformations: 1.03 (0.93, 1.14); Apgar score <7: 1.07 (0.81, 1.39); neonatal mortality: 1.13 (0.90, 1.43); stillbirth: 1.19 (0.95, 1.50)]. Subgroup analysis found similar results in women with either psoriasis or PsA regarding maternal outcomes, and the magnitude of risk estimates seems to be greater in PsA, though without statistical difference. CONCLUSIONS: Pregnant women with psoriasis and PsA have excess risk of adverse maternal events, but not adverse neonatal events. Close monitoring of the mothers' clinical status before and during pregnancy is decidedly required in daily practice.
引用
- Xie W, Huang H, Ji L, et al. Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021. PMID: 33878171. doi:10.1093/rheumatology/keab357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。